Transient hypogammaglobulinemia of infancy

Last updated
Transient hypogammaglobulinemia of infancy
Specialty Immunology   OOjs UI icon edit-ltr-progressive.svg

Transient hypogammaglobulinemia of infancy is a form of hypogammaglobulinemia appearing after birth, leading to a reduction in the level of IgG, and also sometimes IgA [1] [2] and IgM. [3]

Contents

It can result in increased infections, but it can also present without symptoms. [4]

Signs and symptoms

Allergy disorders are the second most common feature, with upper and lower respiratory tract infections accounting for the majority of cases. In addition to developmental delay and cardiac defects, [5] rare manifestations include gastroenteritis, invasive infections, and urinary tract infections. [6] [7] [8]

Causes

It is unknown what specifically causes infantile transient hypogammaglobulinemia. The following are some of the hypothesized mechanisms: 1) defective T cells that prevent B cells from stimulating the proper synthesis of antibodies; 2) maternal IgG suppresses the production of IgG; 3) low levels of vital cytokines; and 4) genetic variations in families predisposed to immunodeficiency. [9] [10] [11]

Mechanism

Normally, a newborn's immunoglobulins come from the mother during pregnancy and wane after birth until 3–6 months of age, when the infant begins to start to produce their own IgG. However, in transient hypogammaglobulinemia of infancy, the IgG synthesis is delayed, and the hypogammaglobulinemia is prolonged beyond age 6 months. [12]

Diagnosis

Transient hypogammaglobulinemia of infancy can be identified if the mean age-specific reference values for serum IgG levels are decreased by more than two standard deviations. [13]

Epidemiology

Transient hypogammaglobulinemia of infancy is thought to affect between 0.061 and 1.1 out of every 1000 live births. [14] [15]

See also

Related Research Articles

<span class="mw-page-title-main">Antibody</span> Protein(s) forming a major part of an organisms immune system

An antibody (Ab) is the secreted form of a B cell receptor; the term immunoglobulin (Ig) can refer to either the membrane-bound form or the secreted form of the B cell receptor, but they are, broadly speaking, the same protein, and so the terms are often treated as synonymous. Antibodies are large, Y-shaped proteins belonging to the immunoglobulin superfamily which are used by the immune system to identify and neutralize antigens such as bacteria and viruses, including those that cause disease. Antibodies can recognize virtually any size antigen with diverse chemical compositions from molecules. Each antibody recognizes one or more specific antigens. Antigen literally means "antibody generator", as it is the presence of an antigen that drives the formation of an antigen-specific antibody. Each tip of the "Y" of an antibody contains a paratope that specifically binds to one particular epitope on an antigen, allowing the two molecules to bind together with precision. Using this mechanism, antibodies can effectively "tag" a microbe or an infected cell for attack by other parts of the immune system, or can neutralize it directly.

<span class="mw-page-title-main">Allergy</span> Immune system response to a substance that most people tolerate well

Allergies, also known as allergic diseases, are various conditions caused by hypersensitivity of the immune system to typically harmless substances in the environment. These diseases include hay fever, food allergies, atopic dermatitis, allergic asthma, and anaphylaxis. Symptoms may include red eyes, an itchy rash, sneezing, coughing, a runny nose, shortness of breath, or swelling. Note that food intolerances and food poisoning are separate conditions.

<span class="mw-page-title-main">Immunoglobulin D</span> Antibody isotype

Immunoglobulin D (IgD) is an antibody isotype that makes up about 1% of proteins in the plasma membranes of immature B-lymphocytes where it is usually co-expressed with another cell surface antibody called IgM. IgD is also produced in a secreted form that is found in very small amounts in blood serum, representing 0.25% of immunoglobulins in serum. The relative molecular mass and half-life of secreted IgD is 185 kDa and 2.8 days, respectively. Secreted IgD is produced as a monomeric antibody with two heavy chains of the delta (δ) class, and two Ig light chains.

<span class="mw-page-title-main">Immunoglobulin E</span> Immunoglobulin E (IgE) Antibody

Immunoglobulin E (IgE) is a type of antibody that has been found only in mammals. IgE is synthesised by plasma cells. Monomers of IgE consist of two heavy chains and two light chains, with the ε chain containing four Ig-like constant domains (Cε1–Cε4). IgE is thought to be an important part of the immune response against infection by certain parasitic worms, including Schistosoma mansoni, Trichinella spiralis, and Fasciola hepatica. IgE is also utilized during immune defense against certain protozoan parasites such as Plasmodium falciparum. IgE may have evolved as a defense to protect against venoms.

<span class="mw-page-title-main">Wiskott–Aldrich syndrome</span> Medical condition

Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema, thrombocytopenia, immune deficiency, and bloody diarrhea. It is also sometimes called the eczema-thrombocytopenia-immunodeficiency syndrome in keeping with Aldrich's original description in 1954. The WAS-related disorders of X-linked thrombocytopenia (XLT) and X-linked congenital neutropenia (XLN) may present with similar but less severe symptoms and are caused by mutations of the same gene.

<span class="mw-page-title-main">X-linked agammaglobulinemia</span> Medical condition

X-linked agammaglobulinemia (XLA) is a rare genetic disorder discovered in 1952 that affects the body's ability to fight infection. As the form of agammaglobulinemia that is X-linked, it is much more common in males. In people with XLA, the white blood cell formation process does not generate mature B cells, which manifests as a complete or near-complete lack of proteins called gamma globulins, including antibodies, in their bloodstream. B cells are part of the immune system and normally manufacture antibodies, which defend the body from infections by sustaining a humoral immunity response. Patients with untreated XLA are prone to develop serious and even fatal infections. A mutation occurs at the Bruton's tyrosine kinase (Btk) gene that leads to a severe block in B cell development and a reduced immunoglobulin production in the serum. Btk is particularly responsible for mediating B cell development and maturation through a signaling effect on the B cell receptor BCR. Patients typically present in early childhood with recurrent infections, in particular with extracellular, encapsulated bacteria. XLA is deemed to have a relatively low incidence of disease, with an occurrence rate of approximately 1 in 200,000 live births and a frequency of about 1 in 100,000 male newborns. It has no ethnic predisposition. XLA is treated by infusion of human antibody. Treatment with pooled gamma globulin cannot restore a functional population of B cells, but it is sufficient to reduce the severity and number of infections due to the passive immunity granted by the exogenous antibodies.

Hypogammaglobulinemia is an immune system disorder in which not enough gamma globulins are produced in the blood. This results in a lower antibody count, which impairs the immune system, increasing risk of infection. Hypogammaglobulinemia may result from a variety of primary genetic immune system defects, such as common variable immunodeficiency, or it may be caused by secondary effects such as medication, blood cancer, or poor nutrition, or loss of gamma globulins in urine, as in nonselective glomerular proteinuria. Patients with hypogammaglobulinemia have reduced immune function; important considerations include avoiding use of live vaccines, and take precautionary measures when traveling to regions with endemic disease or poor sanitation such as receiving immunizations, taking antibiotics abroad, drinking only safe or boiled water, arranging appropriate medical cover in advance of travel, and ensuring continuation of any immunoglobulin infusions needed.

Common variable immunodeficiency (CVID) is an inborn immune disorder characterized by recurrent infections and low antibody levels, specifically in immunoglobulin (Ig) types IgG, IgM, and IgA. Symptoms generally include high susceptibility to pathogens, chronic lung disease, as well as inflammation and infection of the gastrointestinal tract.

<span class="mw-page-title-main">X-linked severe combined immunodeficiency</span> Medical condition

X-linked severe combined immunodeficiency (X-SCID) is an immunodeficiency disorder in which the body produces very few T cells and NK cells.

<span class="mw-page-title-main">Selective immunoglobulin A deficiency</span> Medical condition

Selective immunoglobulin A (IgA) deficiency (SIgAD) is a kind of immunodeficiency, a type of hypogammaglobulinemia. People with this deficiency lack immunoglobulin A (IgA), a type of antibody that protects against infections of the mucous membranes lining the mouth, airways, and digestive tract. It is defined as an undetectable serum IgA level in the presence of normal serum levels of IgG and IgM, in persons older than 4 years. It is the most common of the primary antibody deficiencies. Most such persons remain healthy throughout their lives and are never diagnosed.

<span class="mw-page-title-main">Dysgammaglobulinemia</span> Type of immune disorder

Dysgammaglobulinemia is a type of immune disorder characterized by a reduction in some types of gamma globulins, resulting in heightened susceptibility to some infectious diseases where primary immunity is antibody based.

Immune dysregulation is any proposed or confirmed breakdown or maladaptive change in molecular control of immune system processes. For example, dysregulation is a component in the pathogenesis of autoimmune diseases and some cancers. Immune system dysfunction, as seen in IPEX syndrome leads to immune dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX). IPEX typically presents during the first few months of life with diabetes mellitus, intractable diarrhea, failure to thrive, eczema, and hemolytic anemia. unrestrained or unregulated immune response.

Primary immunodeficiencies are disorders in which part of the body's immune system is missing or does not function normally. To be considered a primary immunodeficiency (PID), the immune deficiency must be inborn, not caused by secondary factors such as other disease, drug treatment, or environmental exposure to toxins. Most primary immunodeficiencies are genetic disorders; the majority are diagnosed in children under the age of one, although milder forms may not be recognized until adulthood. While there are over 430 recognized inborn errors of immunity (IEIs) as of 2019, the vast majority of which are PIDs, most are very rare. About 1 in 500 people in the United States are born with a primary immunodeficiency. Immune deficiencies can result in persistent or recurring infections, auto-inflammatory disorders, tumors, and disorders of various organs. There are currently limited treatments available for these conditions; most are specific to a particular type of PID. Research is currently evaluating the use of stem cell transplants (HSCT) and experimental gene therapies as avenues for treatment in limited subsets of PIDs.

<span class="mw-page-title-main">IgG deficiency</span> Form of immune disorder

IgG deficiency is a form of dysgammaglobulinemia where the proportional levels of the IgG isotype are reduced relative to other immunoglobulin isotypes.

<span class="mw-page-title-main">Isolated primary immunoglobulin M deficiency</span> Medical condition

Isolated primary immunoglobulin M deficiency is a poorly defined dysgammaglobulinemia characterized by decreased levels of IgM while levels of other immunoglobulins are normal. The immunodeficiency has been associated with some clinical disorders including recurrent infections, atopy, Bloom's syndrome, celiac disease, systemic lupus erythematosus and malignancy, but, surprisingly, SIgMD seems to also occur in asymptomatic individuals. High incidences of recurrent upper respiratory tract infections (77%), asthma (47%) and allergic rhinitis (36%) have also been reported. SIgMD seems to be a particularly rare antibody deficiency with a reported prevalence between 0.03% and 0.1%.

<span class="mw-page-title-main">Humoral immune deficiency</span> Medical condition

Humoral immune deficiencies are conditions which cause impairment of humoral immunity, which can lead to immunodeficiency. It can be mediated by insufficient number or function of B cells, the plasma cells they differentiate into, or the antibody secreted by the plasma cells. The most common such immunodeficiency is inherited selective IgA deficiency, occurring between 1 in 100 and 1 in 1000 persons, depending on population. They are associated with increased vulnerability to infection, but can be difficult to detect in the absence of infection.

<span class="mw-page-title-main">Hyper-IgM syndrome type 3</span> Primary immune deficiency disorder

Hyper-IgM syndrome type 3 is a form of hyper IgM syndrome characterized by mutations of the CD40 gene. In this type, Immature B cells cannot receive signal 2 from helper T cells which is necessary to mature into mature B cells.

<span class="mw-page-title-main">Hyper-IgM syndrome type 4</span> Medical condition

Hyper-IgM syndrome type 4 is a form of Hyper IgM syndrome which is a defect in class switch recombination downstream of the AICDA gene that does not impair somatic hypermutation.

<span class="mw-page-title-main">Human milk immunity</span> Protection provided to immune system via human milk

Human milk immunity is the protection provided to the immune system of an infant via the biologically active components in human milk. Human milk was previously thought to only provide passive immunity primarily through Secretory IgA, but advances in technology have led to the identification of various immune-modulating components. Human milk constituents provide nutrition and protect the immunologically naive infant as well as regulate the infant's own immune development and growth.

References

  1. Rapini, Ronald P.; Bolognia, Jean L.; Jorizzo, Joseph L. (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. p. 818. ISBN   978-1-4160-2999-1.
  2. "Transient Hypogammaglobulinemia of Infancy: Immunodeficiency Disorders: Merck Manual Professional" . Retrieved 2008-03-01.
  3. Kiliç SS, Tezcan I, Sanal O, Metin A, Ersoy F (2000). "Transient hypogammaglobulinemia of infancy: clinical and immunologic features of 40 new cases". Pediatr Int. 42 (6): 647–50. doi:10.1046/j.1442-200x.2000.01301.x. PMID   11192522. S2CID   25895833.
  4. Hsueh KC, Chiu HH, Lin HC, Hsu CH, Tsai FJ (2005). "Transient hypogammaglobulinemia of infancy presenting as Staphylococcus aureus sepsis with deep neck infection". J Microbiol Immunol Infect. 38 (2): 141–4. PMID   15843860.
  5. Dorsey, Morna J.; Orange, Jordan S. (2006). "Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy". Annals of Allergy, Asthma & Immunology. 97 (5). Elsevier BV: 590–595. doi:10.1016/s1081-1206(10)61085-x. ISSN   1081-1206. PMID   17165264.
  6. "Clinical features and follow-up of Chinese patients with symptomatic hypogammaglobulinemia in infancy". doi:10.3760/cma.j.issn.0366-6999.2009.16.008.{{cite journal}}: Cite journal requires |journal= (help)
  7. Kutukculer, Necil; Gulez, Nesrin (November 2009). "The outcome of patients with unclassified hypogammaglobulinemia in early childhood". Pediatric Allergy and Immunology. 20 (7): 693–698. doi:10.1111/j.1399-3038.2008.00845.x. ISSN   1399-3038. PMID   19196447. S2CID   25506883.
  8. Artac, Hasibe; Kara, Reyhan; Gokturk, Bahar; Reisli, Ismail (November 2013). "Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy". Clinical and Experimental Medicine. 13 (4): 257–263. doi:10.1007/s10238-012-0200-y. ISSN   1591-9528. PMID   22820757. S2CID   26184302.
  9. Wang, Ling-Jen; Yang, Yao-Hsu; Lin, Yu-Tsan; Chiang, Bor-Luen (March 2004). "Immunological and clinical features of pediatric patients with primary hypogammaglobulinemia in Taiwan" (PDF). Asian Pacific Journal of Allergy and Immunology. 22 (1): 25–31. PMID   15366655 . Retrieved 7 February 2024.
  10. Whelan, M. A.; Hwan, W. H.; Beausoleil, J.; Hauck, W. W.; Mcgeady, S. J. (2006). "Infants Presenting with Recurrent Infections and Low Immunoglobulins: Characteristics and Analysis of Normalization". Journal of Clinical Immunology. 26 (1). Springer Science and Business Media LLC: 7–11. doi:10.1007/s10875-006-8144-1. ISSN   0271-9142. S2CID   24144434.
  11. Wang, Helen C.; Whelan, Meg A.; McGeady, Stephen J.; Yousef, Ejaz (2006). "A 5-month-old boy with recurrent respiratory infections, failure to thrive, and borderline elevated sweat chloride levels". Allergy and Asthma Proceedings. 27 (3): 285–288. doi:10.2500/aap.2006.27.2847. ISSN   1088-5412. PMID   16913275.
  12. Vaillant, Angel A. Justiz; Wilson, Allecia M. (September 4, 2023). "Transient Hypogammaglobulinemia of Infancy". StatPearls Publishing. PMID   31335076 . Retrieved February 7, 2024.
  13. Duse, M.; Iacobini, M.; Leonardi, L.; Smacchia, P.; Antonetti, L.; Giancane, G. (January 1, 2010). "Transient hypogammaglobulinemia of infancy: intravenous immunoglobulin as first line therapy". International Journal of Immunopathology and Pharmacology. 23 (1): 349–353. doi:10.1177/039463201002300134. ISSN   0394-6320. PMID   20378022. S2CID   31079239.
  14. Walker, A M; Kemp, A S; Hill, D J; Shelton, M J (March 1, 1994). "Features of transient hypogammaglobulinaemia in infants screened for immunological abnormalities". Archives of Disease in Childhood. 70 (3). BMJ: 183–186. doi:10.1136/adc.70.3.183. ISSN   0003-9888. PMC   1029737 . PMID   8135560.
  15. Tiller, Thomas L.; Buckley, Rebecca H. (1978). "Transient hypogammaglobulinemia of infancy: Review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up". The Journal of Pediatrics. 92 (3). Elsevier BV: 347–353. doi:10.1016/s0022-3476(78)80417-x. ISSN   0022-3476. PMID   632973.

Further reading